Aging
Navigate
Submit an Article
Research Paper|Volume 13, Issue 16|pp. 20661–20683
METTL21B is a prognostic biomarker and potential therapeutic target in low-grade gliomas
Back to articleFigure 4(4 of 9)
100%
Figure 4
Figure 4.Prognostic value of METTL21B for patients with LGG in TCGA. The effect of METTL21B expression on overall survival (A) and progression-free survival (C) of patients; The ROC curve for OS (B) and PFS (D).